Pharming (PHAR) Gross Profit (2020 - 2026)
Pharming's (PHAR) quarterly Gross Profit came in at $141.5 million in Q2 2026, down 8.74% YoY from $155.0 million in Q2 2025, and up 214991717702740.3% on a QoQ basis from $0.0 in Q1 2026.
Pharming (PHAR) Gross Profit (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of Gross Profit data on file, last reported at $141.5 million in Q2 2026.
- Quarterly Gross Profit fell 8.74% year-over-year to $141.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $317.1 million (down 100.0% YoY) and the FY2025 annual result came in at $330.6 million, up 26.29% from the prior year.
- Gross Profit advanced to $141.5 million in Q2 2026, from $0.0 in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $181300.0 billion in Q4 2024 to a low of $0.0 in Q1 2026.
- A 5-year average of $18183.4 billion and a median of $76.7 million in 2024 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2023 — Gross Profit surged 104509563.56% — and 2025, when it plunged 100.0%.
- Tracing PHAR's Gross Profit over 5 years: stood at $139.7 million in 2022, then surged by 104509563.56% to $146000.0 billion in 2023, then increased by 24.18% to $181300.0 billion in 2024, then sank by 100.0% to $85.4 million in 2025, then soared by 65.66% to $141.5 million in 2026.
- The last three Gross Profit figures came in at $141.5 million (Q2 2026), $0.0 (Q1 2026), and $85.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 141.47 Mn |
| Jun 30, 2026 | 141.47 Mn |
| Mar 31, 2026 | 0.00 |
| Mar 31, 2026 | 0.00 |
| Dec 31, 2025 | 85.40 Mn |
| Dec 31, 2025 | 85.40 Mn |
| Sep 30, 2025 | 90.20 Mn |
| Sep 30, 2025 | 90.20 Mn |
| Jun 30, 2025 | 155.02 Mn |
| Jun 30, 2025 | 155.02 Mn |
| Mar 31, 2025 | 70.77 |
| Mar 31, 2025 | 70.77 |
| Dec 31, 2024 | 181,300.00 Bn |
| Dec 31, 2024 | 181,300.00 Bn |
| Sep 30, 2024 | 68.00 Mn |
| Sep 30, 2024 | 68.00 Mn |
| Jun 30, 2024 | 113.31 Mn |
| Jun 30, 2024 | 113.31 Mn |
| Mar 31, 2024 | 47.20 Mn |
| Mar 31, 2024 | 47.20 Mn |